Ncardia

Ncardia BV is a biotechnology company based in Leiden, the Netherlands, founded in 2017. The company specializes in developing and manufacturing human induced pluripotent stem cell (hiPSC)-based solutions for drug discovery and cell therapy. Ncardia's offerings include disease modeling, assay development, large-scale iPSC manufacturing, and iPSC-based screening. By leveraging hiPSC technology, Ncardia creates predictive human cellular assay systems that aid in the safety and efficacy testing of drug candidates, particularly in the areas of cardiovascular and neural drug screening. This approach enables researchers to incorporate predictive human disease biology into their work, ultimately accelerating the drug discovery and development process.